Gilberto de Castro

2005–2025 年に発表

86
論文数
23,017
被引用数
49
h 指数
85
i10 指数

被引用数

Gilberto de Castro の年別被引用数1926 年: 被引用 1 件1928 年: 被引用 1 件1971 年: 被引用 1 件2001 年: 被引用 3 件2003 年: 被引用 2 件2007 年: 被引用 7 件2008 年: 被引用 16 件2009 年: 被引用 20 件2010 年: 被引用 20 件2011 年: 被引用 15 件2012 年: 被引用 19 件2013 年: 被引用 22 件2014 年: 被引用 16 件2015 年: 被引用 38 件2016 年: 被引用 133 件2017 年: 被引用 257 件2018 年: 被引用 309 件2019 年: 被引用 1,105 件2020 年: 被引用 1,458 件2021 年: 被引用 1,435 件2022 年: 被引用 1,056 件2023 年: 被引用 759 件2024 年: 被引用 1,282 件2025 年: 被引用 635 件2026 年: 被引用 17 件1927 年は被引用が無いため表示していません1929〜1970 年は被引用が無いため表示していません1972〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません2004〜2006 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,753 件、この内訳の 19.9%中国: 引用元論文 1,964 件、この内訳の 14.2%イタリア: 引用元論文 849 件、この内訳の 6.1%日本: 引用元論文 781 件、この内訳の 5.6%フランス: 引用元論文 675 件、この内訳の 4.9%イギリス: 引用元論文 667 件、この内訳の 4.8%ドイツ: 引用元論文 584 件、この内訳の 4.2%スペイン: 引用元論文 562 件、この内訳の 4.1%カナダ: 引用元論文 454 件、この内訳の 3.3%オーストラリア: 引用元論文 391 件、この内訳の 2.8%韓国: 引用元論文 385 件、この内訳の 2.8%オランダ: 引用元論文 347 件、この内訳の 2.5%
0%19.9%その他 24.8%

分野

  • Medicine82.4%
  • Biochemistry, Genetics and Molecular Biology11.5%
  • Immunology and Microbiology2.9%
  • Engineering0.6%
  • Computer Science0.5%
  • Dentistry0.4%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers18.5%
  • Lung Cancer Treatments and Mutations9.5%
  • Lung Cancer Research Studies6.1%
  • Lung Cancer Diagnosis and Treatment4.4%
  • Head and Neck Cancer Studies3.4%
  • Immunotherapy and Immune Responses3.2%
  • その他54.9%

共著者

全論文

検索で開く
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi ほか 119 名 - The Lancet 2019 被引用: 3,211

  2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Per Bergström, Daniel Betticher, Л. В. Болотина, Igor Bondarenko, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andrés F. Cardona, Gilberto de Castro, Hugo R. Castro, Filiz Çay Şenler, Carlos Alexandre Sydow Cerny, Alvydas Česas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao‐Hua Chiu, Byoung Chul Cho, Saulius Cicėnas, Daniel Ciurescu, Graham Cohen, Marcos André Costa, Pongwut Danchaivijitr, Flávia De Angelis, Sérgio Jobim Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, S. A. Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo dos Santos Fernandes, Carlos Gil Ferreira, Fábio Franke, H. Freitas, Yasuhito Fujisaka, Héctor Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Göker, Tuncay Göksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Håkan Griph, Mahmut Gümüş, Jacqueline A. Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernández Hernández, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike ほか 158 名 - The Lancet 2019 被引用: 3,334

  3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet 2015 被引用: 6,537

  4. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 490

  5. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 318

  6. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,152

  7. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,041

  8. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

    著者: , , , , , , - European Journal of Cancer 2012 被引用: 565

  9. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gustavo Werutsky, Sérgio Jobim Azevedo, Fábio Franke, Joilda Batista De Almeida Rego, Pedro Rafael Martins De Marchi, Gustavo Dix Junqueira, Fernanda Maris Peria, Leandro Brust, Parneet Cheema, Mark Doherty, Ambika Parmar, Ines B. Menjak, Natasha B. Leighl, Jason Agulnik, Shun Lü, Zhigang Han, Jiuwei Cui, Li Zhang, Ying Cheng, Gongyan Chen, Helong Zhang, Yu Yao, Chengping Hu, Qiming Wang, Xin Zhang, Yong Zhang, Jianying Zhou, Kejing Ying, Yun Fan, Yan Wang, Ziping Wang, Ji‐Feng Feng, Yingying Du, Lin Wu, Cheng Zhi Huang, Xiangdong Zhou, M. Pérol, Julien Dômont, Corinne Lamour, Julien Dutilh, Youssef Oulkhouir, Virginie Westeel, D. Carmier, Bruno Coudert, Aurélie Lagrange, Dominique Spaëth, Stanislas Ropert, Daniel C. Christoph, Jens Kern, Hans‐Georg Kopp, Frank Griesinger, Rainer Wiewrodt, Martin Wermke, Claas Wesseler, Annette Mueller, G Vogel, Victor Lee, Chung Man James Ho, Siu Hong Oscar Chan, Sing Hung Lo, Shi Feng Jonathan Nyaw, Yu Chung Jacky Li, Jair Bar, Maya Gottfried, Julia Dudnik, Alona Zer, Mor Moskovitz, Mirjana Wollner, Ofer Rotem, Sivan Shamai ほか 111 名 - Journal of Clinical Oncology 2024 被引用: 142

  10. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan A. Azambuja, Giuliano Santos Borges, Gilberto de Castro, Suellen Castro, Felipe Melo Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert H. El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier-Valette, Jaafar Bennouna, C. Chouaïd, Alexis B. Cortot, S. Couraud, D. Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux‐Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, J. Madelaine, M. Marcq, E. Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, A. Vergnenègre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Αthanasios Kotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Bettini, Matteo Brighenti, Giulio Cerea, Filippo de Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Héctor Soto Parrà, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi ほか 101 名 - Journal of Clinical Oncology 2024 被引用: 115

  11. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

    著者: , , , , , , , , , , , , , , - Lung Cancer 2019 被引用: 278

  12. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 74

  13. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 71

  14. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

    著者: , , , , , , , , , - British Journal of Cancer 2007 被引用: 958

  15. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2022 被引用: 72

  16. OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2023 被引用: 36

  17. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Lung Cancer 2024 被引用: 67

  18. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

    著者: , , , , , , , , , , , , , , , , - JTO Clinical and Research Reports 2021 被引用: 82

  19. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 被引用: 61

  20. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors

    著者: , , , , , , , , , , , , , , , , - Kidney International 2022 被引用: 59

  21. Meta-omics analysis indicates the saliva microbiome and its proteins associated with the prognosis of oral cancer patients

    著者: , , , , , , , , , , , , , , , , , , , , , - Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2021 被引用: 51

  22. Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jay W. Fox, Ricardo Della Coletta, Adriana Franco Paes Leme - Nature Communications 2018 被引用: 198

  23. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 392

  24. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 92